Base de dados : MEDLINE
Pesquisa : E01.370.225.812.735.550 [Categoria DeCS]
Referências encontradas : 22516 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2252 ir para página                         

  1 / 22516 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29278907
[Au] Autor:Chojecka A; Tarka P; Kierzkowska A; Nitsch-Osuch A; Kanecki K
[Ad] Endereço:National Institute of Public Health ­ National Institute of Hygiene, Department of Bacteriology, Warsaw, Poland
[Ti] Título:Neutralization efficiency of alcohol based products used for rapid hand disinfection
[So] Source:Rocz Panstw Zakl Hig;68(4):389-394, 2017.
[Is] ISSN:0035-7715
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Background: Alcohols are the most commonly used active substances in preparations for quick hand disinfection. They should be bactericidal in very short contact time. PN-EN 13727 + A2: 2015-12 standard, for testing hygienic and surgical handrub disinfection preparations, provides mandatory test conditions of disinfectants in contact times with the range of 30 s to 60 s (hygienic handrub disinfection) and 60 s to 5 min (surgical handrub disinfection). A short contact times for hand hygiene products require a short time of neutralization process. For contact times less than or equal to 10 minutes, the estimated neutralization time is 10 s ± 1 s. Neutralization is a process that abolishes the action of disinfectants. Correct application of this process allows for proper use of disinfectants in practice and its biocidal effect. Objectives. Verification of the effectiveness of 10-second neutralization time of alcohol based preparations for hygienic handrub disinfection Materials and Method: Neutralization of two products with different ethanol content (89% and 70%) for hygienic handrub disinfection according to PN-EN 13727 + A2: 2015-12 was investigated. The effectiveness of the neutralizer was assessed by determining toxicity of neutralizer, activity of residual effects of the tested products and their derivatives produced during neutralization (10 s) for test organisms (Staphylococcus aureus ATCC 6538; Pseudomonas aeruginosa ATCC 15442; Enterococcus hirae ATCC 10541; Escherichia coli K12 NCTC 10538) Results: The 10-second neutralization time was sufficient to eliminate the residual activity of products for hygienic handrub disinfection with differentiated ethanol concentration. The neutralizer used did not show toxicity to bacteria and did not produce toxic products with tested preparations after neutralization Conclusions: Conclusions. The use of 10-second neutralization time allows in a precise way designate the contact times for hygienic handrub disinfection products
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Bactérias/efeitos dos fármacos
Etanol/farmacologia
Desinfecção das Mãos
Higiene das Mãos/métodos
Higienizadores de Mão/farmacologia
[Mh] Termos MeSH secundário: Bactérias/crescimento & desenvolvimento
Contagem de Colônia Microbiana
Desinfecção/métodos
Seres Humanos
Testes de Neutralização/métodos
Polônia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Hand Sanitizers); 3K9958V90M (Ethanol)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE


  2 / 22516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28465158
[Au] Autor:Muñoz-Alía MA; Casasnovas JM; Celma ML; Carabaña J; Liton PB; Fernandez-Muñoz R
[Ad] Endereço:Virology Unit, Ramón y Cajal Hospital, Madrid, Spain.
[Ti] Título:Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies.
[So] Source:Virus Res;236:30-43, 2017 05 15.
[Is] ISSN:1872-7492
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Measles virus (MV) remains a leading cause of vaccine-preventable deaths in children. Protection against MV is associated with neutralizing antibodies that preferentially recognize the viral hemagglutinin (MV-H), and to a lesser extent, the fusion protein (MV-F). Although MV is serologically monotypic, 24 genotypes have been identified. Here we report three neutralization epitopes conserved in the more prevalent circulating MV genotypes, two located in the MV-H receptor binding site (RBS) (antigenic site III) and a third in MV-H/MV-F interphase (antigenic site Ia) which are essential for MV multiplication. In contrast, two MV-H neutralization epitopes, showed a genotype-specific neutralization escape due to a single amino acid change, that we mapped in the "noose" antigenic site, or an enhanced neutralization epitope (antigenic site IIa). The monoclonal antibody (mAb) neutralization potency correlated with its binding affinity and was mainly driven by kinetic dissociation rate (k ). We developed an immunoassay for mAb binding to MV-H in its native hetero-oligomeric structure with MV-F on the surface of a MV productive steady-state persistently infected (p.i.) human cell lines, and a competitive-binding assay with serum from individuals with past infection by different MV genotypes. Binding assays revealed that a broad neutralization epitope, in RBS antigenic site, a genotype specific neutralization epitopes, in noose and IIa sites, were immunogenic in natural infection and vaccination and may elicit long-lasting humoral immunity that might contribute to explain MV immunogenic stability. These results support the design of improved measles vaccines, broad-spectrum prophylactic or therapeutic antibodies and MV-used in oncolytic therapies.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/imunologia
Anticorpos Antivirais/imunologia
Hemaglutininas Virais/imunologia
Vírus do Sarampo/imunologia
Sarampo/imunologia
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/imunologia
Epitopos/administração & dosagem
Epitopos/imunologia
Genótipo
Hemaglutininas Virais/administração & dosagem
Hemaglutininas Virais/genética
Seres Humanos
Sarampo/prevenção & controle
Sarampo/virologia
Vacina contra Sarampo/administração & dosagem
Vacina contra Sarampo/imunologia
Vírus do Sarampo/classificação
Vírus do Sarampo/genética
Vírus do Sarampo/isolamento & purificação
Testes de Neutralização
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Epitopes); 0 (Hemagglutinins, Viral); 0 (Measles Vaccine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE


  3 / 22516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29244815
[Au] Autor:Liu CC; You CH; Wang PJ; Yu JS; Huang GJ; Liu CH; Hsieh WC; Lin CC
[Ad] Endereço:Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.
[Ti] Título:Analysis of the efficacy of Taiwanese freeze-dried neurotoxic antivenom against Naja kaouthia, Naja siamensis and Ophiophagus hannah through proteomics and animal model approaches.
[So] Source:PLoS Negl Trop Dis;11(12):e0006138, 2017 12.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In Southeast Asia, envenoming resulting from cobra snakebites is an important public health issue in many regions, and antivenom therapy is the standard treatment for the snakebite. Because these cobras share a close evolutionary history, the amino acid sequences of major venom components in different snakes are very similar. Therefore, either monovalent or polyvalent antivenoms may offer paraspecific protection against envenomation of humans by several different snakes. In Taiwan, a bivalent antivenom-freeze-dried neurotoxic antivenom (FNAV)-against Bungarus multicinctus and Naja atra is available. However, whether this antivenom is also capable of neutralizing the venom of other species of snakes is not known. Here, to expand the clinical application of Taiwanese FNAV, we used an animal model to evaluate the neutralizing ability of FNAV against the venoms of three common snakes in Southeast Asia, including two 'true' cobras Naja kaouthia (Thailand) and Naja siamensis (Thailand), and the king cobra Ophiophagus hannah (Indonesia). We further applied mass spectrometry (MS)-based proteomic techniques to characterize venom proteomes and identify FNAV-recognizable antigens in the venoms of these Asian snakes. Neutralization assays in a mouse model showed that FNAV effectively neutralized the lethality of N. kaouthia and N. siamensis venoms, but not O. hannah venom. MS-based venom protein identification results further revealed that FNAV strongly recognized three-finger toxin and phospholipase A2, the major protein components of N. kaouthia and N. siamensis venoms. The characterization of venom proteomes and identification of FNAV-recognizable venom antigens may help researchers to further develop more effective antivenom designed to block the toxicity of dominant toxic proteins, with the ultimate goal of achieving broadly therapeutic effects against these cobra snakebites.
[Mh] Termos MeSH primário: Antídotos/farmacologia
Antivenenos/farmacologia
Venenos Elapídicos/química
Proteoma
Mordeduras de Serpentes/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antídotos/química
Antivenenos/química
Cromatografia Líquida de Alta Pressão
Cromatografia Líquida
Modelos Animais de Doenças
Venenos Elapídicos/envenenamento
Liofilização
Seres Humanos
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Testes de Neutralização
Taiwan
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antidotes); 0 (Antivenins); 0 (Elapid Venoms); 0 (Proteome)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0006138


  4 / 22516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29267277
[Au] Autor:Um J; Chun BC; Lee YS; Hwang KJ; Yang DK; Park JS; Kim SY
[Ad] Endereço:Division of Zoonoses, Center for Immunology & Pathology, Korea National Institute of Health, Cheongju-si, Chungcheongbuk-do, Republic of Korea.
[Ti] Título:Development and evaluation of an anti-rabies virus phosphoprotein-specific monoclonal antibody for detection of rabies neutralizing antibodies using RFFIT.
[So] Source:PLoS Negl Trop Dis;11(12):e0006084, 2017 12.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Rabies is a major public health problem with a fatality rate close to 100%; however, complete prevention can be achieved through pre- or post-exposure prophylaxis. The rapid fluorescent focus inhibition test (RFFIT) is one of the recommended testing methods to determine the production of neutralizing antibodies after vaccination. Here, we report the development of a new monoclonal antibody (mAb) designed to react specifically with Rabies virus (RABV) phosphoprotein (P protein), and the evaluation of its applicability to the RFFIT and its effectiveness as a diagnostic reagent for human rabies. METHODOLOGY/PRINCIPAL FINDINGS: The mAb KGH P 16B8 was produced to target the P protein of the Korean KGH RABV strain. An indirect immunofluorescence assay (IFA) was conducted to detect various strains of RABV in various cell lines. Alexa-conjugated KGH P 16B8 (16B8-Alexa) was developed for the RFFIT. The IFA test could detect RABV up to a 1:2,500 dilution, with a detection limit comparable to that of a commercial diagnostic reagent. The sensitivity, specificity, positive predictive value, and negative predictive value of the RFFIT using 16B8-Alexa in 414 clinical specimens were 98.67%, 99.47%, 99.55%, and 98.42%, respectively. The results of the RFFIT with 16B8-Alexa were strongly correlated with those obtained using an existing commercial diagnostic reagent (r = 0.995, p<0.001). CONCLUSIONS/SIGNIFICANCE: The mAb developed in this study shows high sensitivity and specificity, confirming its clinical utility with the RFFIT to measure the rabies neutralizing antibody titer and establish a diagnosis in human. Thus, 16B8-Alexa is expected to serve as an alternative diagnostic reagent that is widely accessible, with potentially broad applications beyond those of the RFFIT in Korea. Further studies with 16B8-Alexa should provide insight into the immunological mechanism of the P protein of Korean RABV.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/imunologia
Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Técnica Indireta de Fluorescência para Anticorpo/métodos
Testes de Neutralização/métodos
Fosfoproteínas/imunologia
Vírus da Raiva/imunologia
Raiva/prevenção & controle
Proteínas Estruturais Virais/imunologia
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/imunologia
Profilaxia Pós-Exposição/métodos
Raiva/virologia
Vacinas Antirrábicas/imunologia
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (P phosphoprotein, Rabies virus); 0 (Phosphoproteins); 0 (Rabies Vaccines); 0 (Viral Structural Proteins)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180210
[Lr] Data última revisão:
180210
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0006084


  5 / 22516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29051051
[Au] Autor:Sun Z; Yan L; Tang J; Qian Q; Lenberg J; Zhu D; Liu W; Wu K; Wang Y; Lu S
[Ad] Endereço:Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO, 80206, United States. Electronic address: sunz@njhealth.org.
[Ti] Título:Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies.
[So] Source:Virus Res;243:75-82, 2018 01 02.
[Is] ISSN:1872-7492
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:HIV/AIDS has become a worldwide pandemic. Before an effective HIV-1 vaccine eliciting broadly neutralizing monoclonal antibodies (bnmAbs) is fully developed, passive immunization for prevention and treatment of HIV-1 infection may alleviate the burden caused by the pandemic. Among HIV-1 infected individuals, about 20% of them generated cross-reactive neutralizing antibodies two to four years after infection, the details of which could provide knowledge for effective vaccine design. Recent progress in techniques for isolation of human broadly neutralizing antibodies has facilitated the study of passive immunization. The isolation and characterization of large panels of potent human broadly neutralizing antibodies has revealed new insights into the principles of antibody-mediated neutralization of HIV. In this paper, we review the current effective techniques in broadly neutralizing antibody isolation.
[Mh] Termos MeSH primário: Anticorpos Anti-HIV/isolamento & purificação
Infecções por HIV/imunologia
HIV-1/imunologia
Técnicas Imunológicas
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/imunologia
Anticorpos Neutralizantes/isolamento & purificação
Anticorpos Anti-HIV/imunologia
Infecções por HIV/virologia
HIV-1/genética
Seres Humanos
Técnicas Imunológicas/métodos
Técnicas Imunológicas/tendências
Testes de Neutralização
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (HIV Antibodies)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171021
[St] Status:MEDLINE


  6 / 22516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455139
[Au] Autor:Kocazeybek B; Dinc HO; Ergin S; Saribas S; Ozcabi BT; Cizmecigil U; Altan E; Atalik K; Yüksel P; Taner Z; Karakullukcu A; Sirekbasan S; Turan N; Cagatay P; Imamova N; Evliyaoglu O; Yilmaz H
[Ad] Endereço:Istanbul University, Cerrahpasa Medical Faculty, Department of Medical Microbiology, Istanbul, Turkey. Electronic address: bzeybek@istanbul.edu.tr.
[Ti] Título:Evaluation of Adenovirus-36 (Ad-36) antibody seropositivity and adipokine levels in obese children.
[So] Source:Microb Pathog;108:27-31, 2017 Jul.
[Is] ISSN:1096-1208
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Adenovirus 36 (Ad-36) has recently been suggested as a possible contributor to the current obesity epidemic. The aim of this study was to investigate the prevalence of Ad-36 antibodies in obese children, as well as investigate the role of serum leptin and lipid levels in Ad-36-obesity. Seventy-one obese children and 62 non-obese children were included as the patient group (PG), including the healthy control group (HCG), respectively. Simultaneously, Ad-36 antibodies and adipokine levels were assessed with serum neutralization assays (SNA) and ELISA. Ad-36 antibody was detected in 9 patients (12.7%) and 1 patient (1.6%) in both the PG and HCG, respectively, while a significant difference was detected between groups (p < 0.05). Although serum LDL, total cholesterol, triglycerides and leptin levels were detected significantly higher, adiponectin level was detected paradoxically lower in the PG. However, a significant difference was not detected for lipids and leptin levels; adiponectin levels were found to be significantly lower in Ad-36 antibody-positive PG (p < 0.05). In conclusion, we suggest there is an association between Ad-36 and obesity in children, including IL-6 levels increasing in obese children with Ad-36 seropositivity. Conversely, adiponectin levels in obese children with Ad-36 seropositivity were higher. As such, there is a need for studies to understand the mechanisms underlying this observation.
[Mh] Termos MeSH primário: Adenovírus Humanos/imunologia
Adipocinas/sangue
Anticorpos Antivirais/sangue
Obesidade/sangue
Obesidade/epidemiologia
Obesidade/virologia
[Mh] Termos MeSH secundário: Infecções por Adenovirus Humanos/complicações
Infecções por Adenovirus Humanos/virologia
Adiponectina/sangue
Adolescente
Índice de Massa Corporal
Estudos de Casos e Controles
Criança
Colesterol/sangue
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Interleucina-6/sangue
Leptina/sangue
Lipídeos/sangue
Masculino
Testes de Neutralização
Prevalência
Fatores de Risco
Triglicerídeos/sangue
Turquia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ADIPOQ protein, human); 0 (Adipokines); 0 (Adiponectin); 0 (Antibodies, Viral); 0 (Interleukin-6); 0 (Leptin); 0 (Lipids); 0 (Triglycerides); 97C5T2UQ7J (Cholesterol)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE


  7 / 22516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463713
[Au] Autor:Liu J; Shi H; Chen J; Zhang X; Ji Z; Yuan J; Shi D; Cao L; Zhu X; Dong H; Wang X; Zhang J; Feng L
[Ad] Endereço:State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences, Harbin 150001, China; Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, 678 Haping Road, Xiangfang District, Harbin 150069, China.
[Ti] Título:Neutralization of genotype 2 porcine epidemic diarrhea virus strains by a novel monoclonal antibody.
[So] Source:Virology;507:257-262, 2017 07.
[Is] ISSN:1096-0341
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Porcine epidemic diarrhea virus (PEDV) has two genotypes, G1 and G2. To research the immunogenicity differences of PEDV G1 and G2 genotype strains and obtain a neutralizing monoclonal antibody (mAb), we inoculated specific-pathogen-free BALB/c mice with a newly emerged strain, PEDV-LNCT2. After immunizations, cells from the spleen of the mice were fused with SP2/0 myeloma cells. Following culturing and subcloning, a strain, 1B9, secreting neutralizing antibody, was obtained. The 1B9 mAb neutralized new variant genotype 2 PEDV strains (LNCT2, LNSY, and Hjms), but it did not neutralize a genotype 1 PEDV strain (CV777), in vitro. Results showed that the epitope recognized by the 1B9 mAb lies in the spike protein, and that it is a conformational epitope. These findings confirm that allelic differences in the PEDV S gene between the G1 and G2 genotype strains led to changes in the S protein and, thus, differences in its immunogenicity.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/análise
Anticorpos Antivirais/análise
Infecções por Coronavirus/veterinária
Vírus da Diarreia Epidêmica Suína/isolamento & purificação
Doenças dos Suínos/virologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Monoclonais/imunologia
Anticorpos Neutralizantes/análise
Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/imunologia
Infecções por Coronavirus/virologia
Epitopos/genética
Epitopos/imunologia
Genótipo
Testes de Neutralização
Vírus da Diarreia Epidêmica Suína/classificação
Vírus da Diarreia Epidêmica Suína/genética
Vírus da Diarreia Epidêmica Suína/imunologia
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Epitopes)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  8 / 22516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28747500
[Au] Autor:Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
[Ad] Endereço:Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA pth@lanl.gov btk@lanl.gov.
[Ti] Título:Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
[So] Source:J Virol;91(19), 2017 Oct 01.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In the search for effective immunologic interventions to prevent and treat HIV-1 infection, standardized reference reagents are a cost-effective way to maintain robustness and reproducibility among immunological assays. To support planned and ongoing studies where clade C predominates, here we describe three virus panels, chosen from 200 well-characterized clade C envelope (Env)-pseudotyped viruses from early infection. All 200 Envs were expressed as a single round of replication pseudoviruses and were tested to quantify neutralization titers by 16 broadly neutralizing antibodies (bnAbs) and sera from 30 subjects with chronic clade C infections. We selected large panels of 50 and 100 Envs either to characterize cross-reactive breadth for sera identified as having potent neutralization activity based on initial screening or to evaluate neutralization magnitude-breadth distributions of newly isolated antibodies. We identified these panels by downselection after hierarchical clustering of bnAb neutralization titers. The resulting panels represent the diversity of neutralization profiles throughout the range of virus sensitivities identified in the original panel of 200 viruses. A small 12-Env panel was chosen to screen sera from vaccine trials or natural-infection studies for neutralization responses. We considered panels selected by previously described methods but favored a computationally informed method that enabled selection of viruses representing diverse neutralization sensitivity patterns, given that we do not know what the neutralization-response profile of vaccine sera will be relative to that of sera from infected individuals. The resulting 12-Env panel complements existing panels. Use of standardized panels enables direct comparisons of data from different trials and study sites testing HIV-1 clade C-specific products. HIV-1 group M includes nine clades and many recombinants. Clade C is the most common lineage, responsible for roughly half of current HIV-1 infections, and is a focus for vaccine design and testing. Standard reference reagents, particularly virus panels to study neutralization by antibodies, are crucial for developing cost-effective and yet rigorous and reproducible assays against diverse examples of this variable virus. We developed clade C-specific panels for use as standardized reagents to monitor complex polyclonal sera for neutralization activity and to characterize the potency and breadth of cross-reactive neutralization by monoclonal antibodies, whether engineered or isolated from infected individuals. We chose from 200 southern African, clade C envelope-pseudotyped viruses with neutralization titers against 16 broadly neutralizing antibodies and 30 sera from chronic clade C infections. We selected panels to represent the diversity of bnAb neutralization profiles and Env neutralization sensitivities. Use of standard virus panels can facilitate comparison of results across studies and sites.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/imunologia
Anticorpos Neutralizantes/imunologia
Anticorpos Anti-HIV/imunologia
HIV-1/imunologia
Testes de Neutralização/métodos
Produtos do Gene env do Vírus da Imunodeficiência Humana/imunologia
[Mh] Termos MeSH secundário: Infecções por HIV/imunologia
Infecções por HIV/prevenção & controle
Infecções por HIV/terapia
HIV-1/classificação
HIV-1/genética
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Neutralizing); 0 (HIV Antibodies); 0 (env Gene Products, Human Immunodeficiency Virus)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171215
[Lr] Data última revisão:
171215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE


  9 / 22516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27777263
[Au] Autor:Fatemi Nasab GS; Salimi V; Abbasi S; Adjami Nezhad Fard F; Mokhtari Azad T
[Ad] Endereço:Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran 14155, Iran.
[Ti] Título:Comparison of neutralizing antibody titers against outbreak-associated measles genotypes (D4, H1 and B3) in Iran.
[So] Source:Pathog Dis;74(8), 2016 Nov.
[Is] ISSN:2049-632X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Despite the accessibility of a promising vaccine, outbreaks of the measles virus (MV) take place even in well-vaccinated populations. D4, H1 and B3 genotypes have been detected regularly in different regions of Iran. These observations highlight the necessity of evaluating the protective efficacy of the vaccine against currently circulating MV genotypes during the elimination phase. A focus reduction neutralization test has been developed to measure the neutralizing antibodies against different genotypes of MV, such as H1, D4, B3 and vaccine strain (A), in children after second doses of measles vaccine. The geometric mean titer (GMT) rates of the sera against D4, H1, B3 and A genotypes were 95.9, 90.5, 32.0 and 76.1, respectively. Low GMTs of antibody against the B3 genotype compared with the other genotypes were indicated. Based on the current study results, the MV antibody titers in the sera of vaccinated cases are sufficient to neutralize all circulating genotypes in Iran; however, neutralizing antibody titers were lower for the B3 genotype than for the H1, D4 and A genotypes. The heterogeneous nature of MV, for instance the nucleotide sequence diversity between different strains, necessitates the evaluation of the protective efficacy of the vaccine against measles B3 genotype in countries where this virus has been the most commonly identified circulating genotype.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Genótipo
Vírus do Sarampo/genética
Vírus do Sarampo/imunologia
Sarampo/epidemiologia
Sarampo/virologia
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/imunologia
Especificidade de Anticorpos/genética
Especificidade de Anticorpos/imunologia
Pré-Escolar
Surtos de Doenças
Feminino
Seres Humanos
Imunoglobulina G/sangue
Imunoglobulina G/imunologia
Imunoglobulina M/sangue
Imunoglobulina M/imunologia
Irã (Geográfico)/epidemiologia
Masculino
Sarampo/sangue
Sarampo/prevenção & controle
Testes de Neutralização
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Immunoglobulin G); 0 (Immunoglobulin M)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  10 / 22516 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28945244
[Au] Autor:Fernandez E; Dejnirattisai W; Cao B; Scheaffer SM; Supasa P; Wongwiwat W; Esakky P; Drury A; Mongkolsapaya J; Moley KH; Mysorekar IU; Screaton GR; Diamond MS
[Ad] Endereço:Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
[Ti] Título:Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
[So] Source:Nat Immunol;18(11):1261-1269, 2017 Nov.
[Is] ISSN:1529-2916
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The Zika virus (ZIKV) epidemic has resulted in congenital abnormalities in fetuses and neonates. Although some cross-reactive dengue virus (DENV)-specific antibodies can enhance ZIKV infection in mice, those recognizing the DENV E-dimer epitope (EDE) can neutralize ZIKV infection in cell culture. We evaluated the therapeutic activity of human monoclonal antibodies to DENV EDE for their ability to control ZIKV infection in the brains, testes, placentas, and fetuses of mice. A single dose of the EDE1-B10 antibody given 3 d after ZIKV infection protected against lethality, reduced ZIKV levels in brains and testes, and preserved sperm counts. In pregnant mice, wild-type or engineered LALA variants of EDE1-B10, which cannot engage Fcg receptors, diminished ZIKV burden in maternal and fetal tissues, and protected against fetal demise. Because neutralizing antibodies to EDE have therapeutic potential against ZIKV, in addition to their established inhibitory effects against DENV, it may be possible to develop therapies that control disease caused by both viruses.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/imunologia
Anticorpos Antivirais/imunologia
Vírus da Dengue/imunologia
Epitopos/imunologia
Proteínas do Envelope Viral/imunologia
Infecção pelo Zika virus/imunologia
[Mh] Termos MeSH secundário: Animais
Encéfalo/imunologia
Encéfalo/virologia
Cercopithecus aethiops
Reações Cruzadas/imunologia
Vírus da Dengue/classificação
Vírus da Dengue/metabolismo
Feminino
Feto/imunologia
Feto/virologia
Interações Hospedeiro-Patógeno/imunologia
Seres Humanos
Masculino
Camundongos
Testes de Neutralização
Gravidez
Multimerização Proteica/imunologia
Testículo/imunologia
Testículo/virologia
Células Vero
Proteínas do Envelope Viral/química
Carga Viral/imunologia
Zika virus/imunologia
Zika virus/fisiologia
Infecção pelo Zika virus/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Viral); 0 (Epitopes); 0 (Viral Envelope Proteins)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171111
[Lr] Data última revisão:
171111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170926
[St] Status:MEDLINE
[do] DOI:10.1038/ni.3849



página 1 de 2252 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde